Voyageur Pharmaceuticals strikes partnership to accelerate contrast media production

Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) announced it has signed a letter of intent with a major multinational pharmaceutical company to enhance efficiencies in the production of contrast media products. The collaboration expands Voyageur's project portfolio and diversifies its product mix. The partnership will allow Voyageur to further develop its suite of contrast media products, including key offerings in barium, iodine, and fullerene drug development...